title: Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study.
abstract: Ductal carcinoma in situ (DCIS) of the breast, a precursor lesion of invasive breast cancer, is a heterogeneous disease in terms of histomorphologic features and biologic behavior. Our aim was to assess the proliferative activity, expressed as topoisomerase IIalpha (Topo IIalpha) immunoreactivity and c-erbB-2 expression in relation to morphologic features and architectural pattern of DCIS. The study included 26 DCIS, which were reclassified according to the recommendations of Consensus Conference. Topo-IIalpha and c-erbB-2 immunoreactivity were detected on paraffin sections. Topo IIalpha was consistently negative in normal ductal epithelium. Topo IIalpha-labeling index (Topo IIalpha-LI) was 0.7+/-0.6% for grade I, 4.3+/-3.9% for grade II, and 13.4+/-8.9 for grade III lesions (P<.01). For mixed nuclear grade DCIS, Topo IIalpha-LI was 6.8+/-4.8. There was no difference in Topo IIalpha-LI between different architectural patterns in low- and intermediate-grade lesions. In high nuclear grade DCIS, there was a progressive increase in Topo IIalpha-LI from solid toward cribriform and comedo-type DCIS. Positive c-erbB-2 immunoreactivity was found in 46% of DCIS, being highest in DCIS with high nuclear grade (78%) and in lesions with extensive necrosis. Topo IIalpha-LI was significantly higher in c-erbB-2-positive lesions (Topo IIalpha-LI- 12.4+/-8.5) as compared with negative lesions (Topo IIalpha-LI- 3.9+/-4.5, P<. 0001). Overexpression of c-erbB-2 and Topo IIalpha is associated with poorly differentiated lesions. Proliferative activity in individual ducts of DCIS depended primarily on the nuclear grade and was independent of architectural patterns of individual ducts in architecturally heterogeneous lesions.
authors.affiliation: Departments of Surgery B and Pathology, Meir General Hospital, affiliated with the Sackler School of Medicine, Tel Aviv University, Israel.
authors.forename: B
authors.initials: B
authors.lastname: Shpitz
authors.forename: Y
authors.initials: Y
authors.lastname: Bomstein
authors.forename: T
authors.initials: T
authors.lastname: Zehavi
authors.forename: J
authors.initials: J
authors.lastname: Bernheim
authors.forename: S
authors.initials: S
authors.lastname: Liverant
authors.forename: Z
authors.initials: Z
authors.lastname: Kaufman
authors.forename: G
authors.initials: G
authors.lastname: Buklan
authors.forename: E
authors.initials: E
authors.lastname: Klein
mesh_terms: D000951:Antigens, Neoplasm; D001943:Breast Neoplasms / Q000201:enzymology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000201:enzymology*; D004250:DNA Topoisomerases, Type II / Q000096:biosynthesis*; D004268:DNA-Binding Proteins; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis*; D008875:Middle Aged; D009336:Necrosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis
chemical_list: D000951:Antigens, Neoplasm; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D007527:Isoenzymes; D018719:Erb-b2 Receptor Tyrosine Kinases